123 related articles for article (PubMed ID: 32684124)
1. COBRA™: a highly potent conditionally active T cell engager engineered for the treatment of solid tumors.
Panchal A; Seto P; Wall R; Hillier BJ; Zhu Y; Krakow J; Datt A; Pongo E; Bagheri A; Chen TT; Degenhardt JD; Culp PA; Dettling DE; Vinogradova MV; May C; DuBridge RB
MAbs; 2020; 12(1):1792130. PubMed ID: 32684124
[TBL] [Abstract][Full Text] [Related]
2. A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice.
Fisher TS; Hooper AT; Lucas J; Clark TH; Rohner AK; Peano B; Elliott MW; Tsaparikos K; Wang H; Golas J; Gavriil M; Haddish-Berhane N; Tchistiakova L; Gerber HP; Root AR; May C
Cancer Immunol Immunother; 2018 Feb; 67(2):247-259. PubMed ID: 29067496
[TBL] [Abstract][Full Text] [Related]
3. A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy.
Frey G; Cugnetti APG; Liu H; Xing C; Wheeler C; Chang HW; Boyle WJ; Short JM
MAbs; 2024; 16(1):2322562. PubMed ID: 38445633
[TBL] [Abstract][Full Text] [Related]
4. Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo.
de Jong G; Bartels L; Kedde M; Verdegaal EME; Gillissen MA; Levie SE; Cercel MG; van Hal-van Veen SE; Fatmawati C; van de Berg D; Yasuda E; Claassen YB; Bakker AQ; van der Burg SH; Schotte R; Villaudy J; Spits H; Hazenberg MD; van Helden PM; Wagner K
Cancer Immunol Immunother; 2021 Jun; 70(6):1569-1581. PubMed ID: 33225419
[TBL] [Abstract][Full Text] [Related]
5. Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3.
Schlereth B; Kleindienst P; Fichtner I; Lorenczewski G; Brischwein K; Lippold S; da Silva A; Locher M; Kischel R; Lutterbüse R; Kufer P; Baeuerle PA
Cancer Immunol Immunother; 2006 Jul; 55(7):785-96. PubMed ID: 16187083
[TBL] [Abstract][Full Text] [Related]
6. Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression.
Ding Z; Sun S; Wang X; Yang X; Shi W; Huang X; Xie S; Mo F; Hou X; Liu A; Jiang X; Tang Z; Lu X
J Hematol Oncol; 2023 Nov; 16(1):115. PubMed ID: 38031188
[TBL] [Abstract][Full Text] [Related]
7. Computational simulations of bispecific T cell engagers by a multiscale model.
Su Z; Almo SC; Wu Y
Biophys J; 2024 Jan; 123(2):235-247. PubMed ID: 38102828
[TBL] [Abstract][Full Text] [Related]
8. Rapid Access to Potent Bispecific T Cell Engagers Using Biogenic Tyrosine Click Chemistry.
Shajan I; Rochet LNC; Tracey SR; Jackowska B; Benazza R; Hernandez-Alba O; Cianférani S; Scott CJ; van Delft FL; Chudasama V; Albada B
Bioconjug Chem; 2023 Dec; 34(12):2215-2220. PubMed ID: 37962868
[TBL] [Abstract][Full Text] [Related]
9. Development of bispecific T cell engagers: harnessing quantitative systems pharmacology.
Qi T; Liao X; Cao Y
Trends Pharmacol Sci; 2023 Dec; 44(12):880-890. PubMed ID: 37852906
[TBL] [Abstract][Full Text] [Related]
10. Targeted chain-exchange-mediated reconstitution of a split type-I cytokine for conditional immunotherapy.
Vasic V; Buldun C; Ritz M; Dickopf S; Georges GJ; Spick C; Peuker A; Meier T; Mayer K; Brinkmann U
MAbs; 2023; 15(1):2245111. PubMed ID: 37608616
[TBL] [Abstract][Full Text] [Related]
11. Superantigen-fused T cell engagers for tumor antigen-mediated robust T cell activation and tumor cell killing.
Zhao WB; Shen Y; Cai GX; Li YM; Liu WH; Wu JC; Xu YC; Chen SQ; Zhou Z
Mol Ther; 2024 Feb; 32(2):490-502. PubMed ID: 38098228
[TBL] [Abstract][Full Text] [Related]
12. HPN328, a Trispecific T Cell-activating Protein Construct Targeting DLL3-Expressing Solid Tumors.
Molloy ME; Aaron WH; Barath M; Bush MC; Callihan EC; Carlin K; Cremin M; Evans T; Gamez Guerrero M; Hemmati G; Hundal AS; Lao L; Laurie P; Lemon BD; Lin SJ; O'Rear J; Patnaik P; Sotelo Rocha S; Santiago L; Strobel KL; Valenzuela LB; Wu CH; Yu S; Yu TZ; Anand BS; Law CL; Sun LL; Wesche H; Austin RJ
Mol Cancer Ther; 2024 Apr; ():. PubMed ID: 38670552
[TBL] [Abstract][Full Text] [Related]
13. Small-molecule-mediated control of the anti-tumour activity and off-tumour toxicity of a supramolecular bispecific T cell engager.
Gong N; Han X; Xue L; Billingsley MM; Huang X; El-Mayta R; Qin J; Sheppard NC; June CH; Mitchell MJ
Nat Biomed Eng; 2024 Feb; ():. PubMed ID: 38378820
[TBL] [Abstract][Full Text] [Related]
14. Uncovering the mode of action of engineered T cells in patient cancer organoids.
Dekkers JF; Alieva M; Cleven A; Keramati F; Wezenaar AKL; van Vliet EJ; Puschhof J; Brazda P; Johanna I; Meringa AD; Rebel HG; Buchholz MB; Barrera Román M; Zeeman AL; de Blank S; Fasci D; Geurts MH; Cornel AM; Driehuis E; Millen R; Straetemans T; Nicolasen MJT; Aarts-Riemens T; Ariese HCR; Johnson HR; van Ineveld RL; Karaiskaki F; Kopper O; Bar-Ephraim YE; Kretzschmar K; Eggermont AMM; Nierkens S; Wehrens EJ; Stunnenberg HG; Clevers H; Kuball J; Sebestyen Z; Rios AC
Nat Biotechnol; 2023 Jan; 41(1):60-69. PubMed ID: 35879361
[TBL] [Abstract][Full Text] [Related]
15. Optimizing Clinical Translation of Bispecific T-cell Engagers through Context Unification with a Quantitative Systems Pharmacology Model.
Liao X; Qi T; Zhou J; Liu C; Cao Y
Clin Pharmacol Ther; 2024 May; ():. PubMed ID: 38751031
[TBL] [Abstract][Full Text] [Related]
16. Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors.
Middelburg J; Kemper K; Engelberts P; Labrijn AF; Schuurman J; van Hall T
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33466732
[TBL] [Abstract][Full Text] [Related]
17. Overcoming the challenges associated with CD3+ T-cell redirection in cancer.
Singh A; Dees S; Grewal IS
Br J Cancer; 2021 Mar; 124(6):1037-1048. PubMed ID: 33469153
[TBL] [Abstract][Full Text] [Related]
18. Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy.
Fucà G; Spagnoletti A; Ambrosini M; de Braud F; Di Nicola M
ESMO Open; 2021 Feb; 6(1):100046. PubMed ID: 33508733
[TBL] [Abstract][Full Text] [Related]
19. Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models.
Schneider D; Xiong Y; Wu D; Hu P; Alabanza L; Steimle B; Mahmud H; Anthony-Gonda K; Krueger W; Zhu Z; Dimitrov DS; Orentas RJ; Dropulić B
Sci Transl Med; 2021 Mar; 13(586):. PubMed ID: 33762438
[TBL] [Abstract][Full Text] [Related]
20. Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
Suurs FV; Lorenczewski G; Bailis JM; Stienen S; Friedrich M; Lee F; van der Vegt B; de Vries EGE; de Groot DA; Lub-de Hooge MN
J Nucl Med; 2021 Apr; 62(12):1797-804. PubMed ID: 33931466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
